Midatech Pharma plc logo
Midatech Pharma plc MTP

Quarterly report 2025-Q4
added 05-14-2026

report update icon

Midatech Pharma plc Long-Term Debt 2011-2026 | MTP

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt Midatech Pharma plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - 4.76 M 714 K 6.16 M 1.57 M 1.44 M 1.49 M 1.01 M - -

All numbers in GBP currency

Indicator range from annual reports

Maximum Minimum Average
6.16 M 714 K 2.45 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
38 K - 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
273 M - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
2.95 M - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
68.2 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
2.42 B - - $ 40.3 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
1.46 M $ 1.63 -4.4 % $ 191 M usaUSA
Biophytis SA Biophytis SA
BPTS
1.83 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
173 M - 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
1.42 B - - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
278 K - -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
20.8 M $ 7.83 -5.21 % $ 214 M israelIsrael
Athira Pharma Athira Pharma
ATHA
338 K - - $ 269 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
653 K $ 3.12 - $ 649 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
124 M - 0.74 % $ 768 M israelIsrael
Exelixis Exelixis
EXEL
173 M $ 51.1 -0.37 % $ 13.9 B usaUSA
Forte Biosciences Forte Biosciences
FBRX
26.2 M $ 23.96 -2.84 % $ 310 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
1.12 M - -32.59 % $ 7.61 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
5.74 M $ 8.9 0.56 % $ 1.08 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
137 M $ 4.4 -7.76 % $ 1.31 B canadaCanada
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
620 M $ 17.3 -5.57 % $ 809 M usaUSA
BioNTech SE BioNTech SE
BNTX
185 M $ 91.99 -0.26 % $ 22.2 B germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
1.98 M $ 3.03 6.32 % $ 283 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
175 M - - - russiaRussia
Gilead Sciences Gilead Sciences
GILD
22.1 B $ 132.06 -0.74 % $ 164 B usaUSA
Advaxis Advaxis
ADXS
8.14 M - -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
15 K $ 3.49 -4.12 % $ 5.75 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
1.93 M - 5.93 % $ 314 M canadaCanada
Grifols, S.A. Grifols, S.A.
GRFS
1.02 B $ 7.79 1.04 % $ 5.29 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
4 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
25.4 M - - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
9.12 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
2.29 M - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
529 K - - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
193 K - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
22.1 M - -39.0 % $ 4.57 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
52.4 M $ 2.3 3.14 % $ 64.2 M usaUSA
Akouos Akouos
AKUS
28.3 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
9.62 M - -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
1.13 M - 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
38.2 M - - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
108 M $ 21.57 -0.55 % $ 2.74 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
210 K - 3.16 % $ 1.9 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
19.3 M $ 9.24 36.48 % $ 264 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
274 K - -11.43 % $ 502 K usaUSA